Alkem Laboratories
Other · 4 quarters tracked · source-linked performance and management context.
Latest revenue
₹3,603 Cr
verified financial record
Quarters tracked
4
source records in the directory
Delivery assessment
0
Across 2 tracked commitments: 0 delivered, 2 missed.
Call date
2026-05-15
latest available source date
Signal trajectory
3 actual quartersCurrent read
0/100
Across 2 tracked commitments: 0 delivered, 2 missed.
Latest source read
What changed this quarter?
Alkem delivered a strong Q4 FY26 with revenue of ₹3,633 crore (+14.6% YoY) and EBITDA of ₹517.4 crore (+32.2% YoY), resulting in an EBITDA margin of 14.24% (+184 bps YoY). India branded generics grew ~10%, outperforming the IPM by 100-150 bps, while international sales surged 25.4% YoY. The successful day-one launch of semaglutide in India captured an 11% unit market share in its first month. Management expects to sustain 100-150 bps outperformance in India and high single-digit US growth in FY27, though geopolitical headwinds may pressure margins. The key risk is rising input costs from global supply chain disruptions, which could limit margin expansion to the 20-21% range.
Colored figures compare against the previous available record. Hover or focus one for the comparison.
Signal
Positive
Revenue
₹3,603 Cr
Source date
2026-05-15
Across the record
Quarter history.
History modules